RE:RE:RE:RE:The multifaceted role of sortilin/neurotensin receptor Thera uses sortilin as an entry point into cells. SORT1+ platform is not dealing with sortilin metabolism or expression. SORT1+ platform's basic principle is to take adavantage of the trafficking role of sortilin expressed on cancer cell membranes, and of its overexpression in some cancer types, especially more advanced cancer. The patent for the SORT1+ platform does not mention sortilin, and it protects a family of peptide sequences combined with a wide variety of possible linkers.
So for another company to try to compete against SORT1+, if it works, they would need to come up with a totally different peptide ligand, so a very different amino acid sequence that could still bind with sortilin while being able to carry a cytotoxic payload. The other possible way would be by developing an anti-sortilin antibody that would be the base for an ADC aiming at sortilin. Then, there would be the question of whether an ADC could be better than TH1902 or other PDCs made out of TH19P01.
All that to say that in the field of targetting sortilin as an entry point into cancer cells and a way to circumvent multi drug resistance, SORT1+ is well ahead right now, maybe alone. And if they get the proof of concept, my guess is that other PDCs derived from TH19P01 will follow rather quickly. The question right now is not the potential competition, it's the proof of concept. This would open so many possibilities, different PDC with different cytotoxic agents, combo therapy with other drugs, combo therapy involving two PDCs with different payloads, flexibility in regimens for better tolerability in some patients. The use of siRNA to shut down pro cancer pathways, or mRNA to amplify anti cancer pathways. That's why the proof of concept is much more important than the simple efficacy of TH1902. Proof of concept would be a great thing for cancer patients, and for investors it would open the door to a real hope of an Immunomedics scenario.
https://patents.google.com/patent/WO2017088058A1/en
realitycheck4u wrote: SPCEO - get it here. https://onlinelibrary.wiley.com/doi/epdf/10.1002/jcp.30344